Anti-TNFs in axial spondyloarthritis.

about

Anti-TNFs in axial spondyloarthritis.

Item

http://www.wikidata.org/entity/Q38311916

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Anti-TNFs in axial spondyloarthritis.

@en

type

Item

label

Anti-TNFs in axial spondyloarthritis.

@en

prefLabel

Anti-TNFs in axial spondyloarthritis.

@en

P1476

Anti-TNFs in axial spondyloarthritis.

@en

P2093

Christian Muschitz

http://www.w3.org/2001/XMLSchema#string

Jürgen Rech

http://www.w3.org/2001/XMLSchema#string

Roland Kocijan

http://www.w3.org/2001/XMLSchema#string

P2860

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial.

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab.

Swedish registers to examine drug safety and clinical issues in RA.

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.

Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years.

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.

P2888

s10354-014-0338-1

P304

10-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10354-014-0338-1

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

165

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270597038

http://www.w3.org/2001/XMLSchema#string

P6179

1034169786

http://www.w3.org/2001/XMLSchema#string

P698

25572548

http://www.w3.org/2001/XMLSchema#string

P921

TNF inhibitor

Anti-TNFs in axial spondyloarthritis.

about

Anti-TNFs in axial spondyloarthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698

P921